HIV-1/2 Ab Diff

If your initial HIV screening test came back reactive, this is the test that tells you what is actually happening. A reactive screen alone does not confirm infection, and it cannot tell whether antibodies are pointed at HIV-1 (the strain behind more than 99.9% of US diagnoses) or HIV-2 (a less common, mostly West African strain that responds differently to medication).

The HIV-1/2 antibody differentiation assay sits in the middle of the standard testing algorithm. It confirms whether HIV antibodies are present and identifies which virus your immune system is responding to. That distinction matters because the two viruses behave differently and require different treatment choices.

What the Test Actually Measures

This test detects antibodies your immune system has made against HIV-1 and HIV-2. It does not measure the virus directly, and it does not pick up infection in the first few weeks after exposure when antibodies have not yet developed. It is qualitative, meaning the result is reactive, non-reactive, or indeterminate for each virus type, rather than a number on a scale.

The test is run on a blood sample using assays such as Geenius or Multispot. It is the second step in the CDC and APHL recommended HIV testing algorithm: a fourth-generation antigen and antibody screen first, then this differentiation test if the screen is reactive, and HIV-1 nucleic acid testing (NAT, which detects viral genetic material) if the differentiation test is negative or indeterminate.

Why HIV-1 vs HIV-2 Distinction Matters

HIV-1 and HIV-2 are related viruses, but they are not the same disease. HIV-2 is genetically distinct, generally progresses more slowly, and does not respond to certain antiretroviral medications that work against HIV-1. Treating HIV-2 with an HIV-1 regimen can fail outright. Identifying the correct virus type is the difference between a treatment plan that works and one that does not.

In US laboratory data covering more than 504,000 specimens, the Geenius assay had a 99.4% positive predictive value for HIV-1 and only a 4.3% positive predictive value for HIV-2, meaning HIV-2 indeterminate or untypable patterns are far more common than true HIV-2 infections. This is why a result suggesting HIV-2 always needs follow-up testing rather than immediate action.

Catching Dual HIV-1 and HIV-2 Infection

Dual infection with both HIV-1 and HIV-2 is rare but real. In Swiss surveillance data, 25.7% of HIV-2 cases were actually dual HIV-1 and HIV-2 infections. In nearly all of those dual cases, HIV-1 RNA was detectable at diagnosis.

Here is the catch: an alternative algorithm that runs HIV-1 RNA before differentiation testing, and only differentiates if RNA is undetectable, would have missed at least 7 of 9 dual infections in that cohort. If you have any reason to suspect HIV-2 exposure (origin or travel in West Africa, or a sexual partner from there), early antibody differentiation is the only reliable way to identify a dual infection.

Acute Infection: Where This Test Has a Blind Spot

Antibody differentiation cannot diagnose very early HIV. In a US prospective study of 37,876 screened individuals, more than half (52.2%) of specimens that screened positive but came back non-reactive on Multispot turned out to have detectable HIV-1 RNA. These were acute infections in the window before antibodies had formed.

If you have had a possible recent exposure (in the last few weeks) and your screening test is reactive but the differentiation test is negative or indeterminate, that is exactly when HIV-1 NAT becomes essential. A negative differentiation test does not rule out infection in the early window.

Result Interpretation

Because this is a qualitative confirmation test rather than a numeric biomarker, results fall into categories rather than tiers. Lab-to-lab variation in assay version (Geenius, Multispot, Inno-Lia) can affect indeterminate rates, so always interpret results within the same testing pathway used by the lab that ran your sample.

When Results Can Be Misleading

• Acute infection window: if the exposure was recent (within roughly the last 3 to 6 weeks), antibodies may not yet have formed. The test can be falsely non-reactive while the virus is replicating. HIV-1 RNA testing covers this window.
• HIV-2 indeterminate bands: cross-reactivity from HIV-1 antibodies can produce HIV-2 bands that suggest HIV-2 when only HIV-1 is present. In US labs, this happens far more often than true HIV-2 infection.
• Very early antiretroviral therapy in acute infection: in research cohorts, starting treatment within roughly 60 days of acquiring HIV-1 can blunt or delay full antibody development, which can produce confusing differentiation patterns over time.
• Sample handling and assay version: different labs use different versions of differentiation assays (Multispot, Geenius, Inno-Lia, VioOne), and indeterminate rates vary. If a result is indeterminate, retesting at the same lab or moving directly to NAT is usually more informative than switching assays.

What to Do With an Abnormal Result

A confirmed HIV-1 result starts a clear, well-supported pathway: you connect with an HIV specialist, run a baseline viral load and CD4 count, and start antiretroviral therapy. International guidelines recommend immediate ART for everyone with HIV using an integrase strand transfer inhibitor based regimen plus two nucleoside or nucleotide reverse transcriptase inhibitors. With consistent therapy, viral load typically drops to undetectable, which protects your immune system and prevents transmission to partners.

A confirmed HIV-2 or dual infection requires a specialist familiar with HIV-2, because some standard HIV-1 medications (such as non-nucleoside reverse transcriptase inhibitors) do not work against HIV-2. The treatment plan and viral load monitoring are different. If your screen was reactive, your differentiation result is indeterminate, or you have any reason to suspect HIV-2 exposure, push for NAT and HIV-2 specific follow-up rather than waiting.

Tracking Over Time

Once HIV antibodies develop, they almost always remain detectable for life, even with successful treatment. So this test is not something you retest serially in the way you would track a number that goes up or down. After confirmation, the markers you actually monitor are HIV viral load (every 3 to 6 months once stable on therapy) and CD4 count (at diagnosis and periodically after).

If you are HIV-negative and at ongoing risk (new partners, partners of unknown status, injection drug use, partners from HIV-2 endemic regions), retesting with the full algorithm at least annually, and every 3 to 6 months if you are at higher risk, gives you the earliest possible window to act. If you are on PrEP, your testing schedule is built into the prescription follow-up: every 3 months.